Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis

著者: Linjie Zhao, Shuang Huang, Shenglin Mei, Zhengnan Yang, Lian Xu, Nianxin Zhou, Qilian Yang, Qiuhong Shen, Wei Wang, Xiaobing Le, Wayne Bond Lau, Bonnie Lau, Xin Wang, Tao Yi, Xia Zhao, Yuquan Wei, Margaret Warner, Jan-Ακε Gustafsson, Shengtao Zhou - Proceedings of the National Academy of Sciences, PNAS 2018 被引用: 75

Significance Cancer metastases have caused the major mortality rate for cancer patients, with limited options of treatment and unsatisfactory therapeutic efficacy. Unlike the tumor-promoting role of estrogen receptor (ER)α, ERβ has shown potent antitumor effects in many cancers. In this study, we showed that the selective ERβ agonist LY500307 could potently suppress lung metastasis of cancer by recruitment of antitumor neutrophils to the metastatic niche. These chemotactic effects of LY500307 for neutrophils were primarily mediated by ERβ activation-induced IL-1β release by the tumor cells. Our study provides the rationale that pharmacological activation of ERβ could augment innate immunity to suppress cancer metastatic colonization to lung, implicating the potential use of selective ERβ agonists for the treatment of cancer patients with metastasis.